Inexia aims to develop intranasally administered orexin positive modulators for the treatment of neurological diseases.
The orexin system is a key regulator of behavioural arousal, wakefulness and sleep. The loss of the orexin neurons has been shown to be strongly linked to multiple neurological conditions including narcolepsy. In this indication, orexin receptors remain intact and functional, providing an opportunity for therapeutic intervention.
The primary target indication of narcolepsy is characterized by frequent transitions between states of wakefulness and sleep and the inability of maintaining a wakeful state. Narcoleptic patients experience excessive daytime sleepiness (EDS), manifesting as attacks of falling asleep at unpredictable times, as well as often suffering from cataplexy, a sudden debilitating but transient weakening of muscle tone that can cause sufferers to collapse. An orexin positive modulator will aim to restore orexin levels in the brain and improve symptoms.
The company is founded by Medicxi in collaboration with Sosei Heptares and Optinose, and follows the asset centric model of outsourcing R&D activities. The partnership with Sosei Heptares leverages unique GPCR structure-based drug design (SBDD) capability for the discovery and development of promising drug candidates which will be delivered using Optinose's unique clinically validated intranasal Exhalation Delivery System (EDS).
Medicxi is based in London, Geneva and Jersey. The firm's mission is to invest across the full healthcare continuum. Medicxi was established by the former Index Ventures life sciences team and continues to manage the legacy life sciences portfolio of Index Ventures. Medicxi has launched two new funds - Medicxi Ventures 1 (MV1) and Medicxi Growth 1 (MG1) – that focus respectively on early-stage and late-stage investments in life sciences. GSK, Johnson & Johnson and Novartis, three of the world’s largest pharmaceutical companies back Medicxi along with Verily, an Alphabet company. These companies, whilst participating in the SABs of the Medicxi funds, do not receive any preferential rights to the portfolio companies. Medicxi’s team has been investing in life sciences for over 20 years and has backed many successful companies, including Genmab (NASDAQ Copenhagen: GEN), PanGenetics (sold to AbbVie), Micromet (sold to Amgen), Molecular Partners (SWX: MOLN), XO1 (sold to Janssen), Minerva Neurosciences (NASDAQ: NERV), Padlock Therapeutics (sold to Bristol-Myers Squibb) and Impact Biomedicines (sold to Celgene).
Please see www.medicxi.com for more information.
About Sosei Heptares
We are an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications. Its leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK and Zurich, Switzerland.
“Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.soseiheptares.com.
Optinose (NASDAQ: OPTN) is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. The innovative mechanism of action of the Optinose Exhalation Delivery system (EDS) technology is designed to enable broad, consistent drug delivery high and deep in the nasal passages, leveraging the mucosal surfaces as a potential target for the treatment of local, systemic, and central nervous system diseases. Please visit www.optinose.com to learn more.